Agios Appoints Jeffrey Capello to Board of Directors
19 avr. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
13 avr. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Publishes 2023 Environmental, Social and Governance (ESG) Report
03 avr. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Report Highlights Continued Progress on Patient Access, Health Equity, Diversity and Flexibility – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the...
Agios to Participate in March Investor Conferences
02 mars 2023 08h26 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day
28 févr. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Reports Fourth Quarter and Full Year 2022 Financial Results
23 févr. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND® (mitapivat) in Sickle Cell Disease – – On Track to Complete Enrollment in Phase 3 ENERGIZE and ENERGIZE-T Studies of PYRUKYND® in...
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
02 févr. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases
08 janv. 2023 20h00 HE
|
Agios Pharmaceuticals, Inc.
– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency – –...
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
03 janv. 2023 17h57 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
21 déc. 2022 08h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...